Nearly all primary brain lymphomas in acquired immunodeficiency syndrome (AIDS) patients are associated with Epstein-Barr virus (EBV). The role of EBV in lymphomagenesis is not totally elucidated. One possible mechanism is the overexpression of the BCL-2 oncoprotein, because the latent membrane protein 1 (LMP1) has been reported to transactivate the bcl-2 gene in vitro. To study the interrelationship between LMPl and BCL-2 in vivo, we have analyzed and compared their expression in 11 AIDS-related primary brain lymphomas and 57 AIDS-related systemic lymphomas by immunoperoxidase technique on frozen sections. In AIDSrelated primary brain lymphomas, LMPl and BCL-2 OST ACQUIRED immuncdeficiency syndrome (AIDS)-related lymphomas are characterized by a B-cell phenotype, high-grade malignancy, and an extranodal localization."5 The association with the Epstein-Barr virus (EBV), observed in 67% of cases in one study,6 varies significantly according to the primary localization and the histologic type?3637 EBV has been detected in more than 90% of AIDSrelated primary brain lymphomas (AR-PBL). proliferative rate.I4 This finding opens new perspectives in EBV-related oncogenesis.
were expressed in all cases but 1. All positive cases exhibited morphologic immunoblastic features. In contrast, the only negative case was histologically close to Burkitt's lymphoma. In systemic lymphomas, LMPl was expressed in 21 cases, whereas BCL-2 was positive in only 3 cases, all of which were extranodal. These results indicate that, in addition to the histologic type, the role of EBV genes and BCL-2 expression in lymphomatous cells differ as a function of their localization. In AIDS-related primary brain lymphomas, this correlation between LMPl and BCL-2 overexpression may have a major implication in lymphomagenesis.
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proliferative rate.I4 This finding opens new perspectives in EBV-related oncogenesis.
To search for a correlation between LMPl and BCL-2 expression, we have analyzed 11 AR-PBL and 57 AIDSrelated systemic lymphomas (AR-SL). We show here a high expression of both LMPl and BCL-2 in the AIDS-related primary brain lymphomas.
MATERIALS AND METHODS
Tumor specimens and histology. Sixty-eight cases of AlDS-related non-Hodgkin lymphomas were analyzed. Eleven were AR-PBL from a series of autopsies from the neuropathology laboratory (PitiB-Salp&tri&re Hospital) and 57 others cases were AR-SL from the French Study Group of HIV-Associated Tumors. Cases of disseminated lymphomas with secondary brain involvement were excluded. In all cases, part of the sample was snap-frozen in liquid nitrogen and kept at -80°C until it was used for immunophenotypic and genotypic studies. The rest was routinely processed after formalin fixation and paraffin embedding. Conventional histology was performed on paraffin-embedded material stained with haematoxylin-eosin and Giemsa's method. All cases were classified according to the updated Kiel and Working Formulation riter ria.'^.'^ lmmunophenorypic study. Immunophenotypic studies were performed on paraffin-embedded or frozen sections using either the avidin biotin peroxidase or alkaline phosphatasdanti-alkaline phosphatase techniques (APAAP). The immunoperoxidase method using a commercially available Kit (Vectastain; ABC Vector Laboratories, Burlingame, CA) was performed on paraffin-embedded material with monoclonal antibodies (MoAbs) directed against CD20 (L26). CD45RO (UCHL1) antibodies and on frozen section with CD3 MoAb (leu4; Becton Dickinson), LMPl (CS1-4). and BCL-2 antibody (124) from Dakopatts laboratory (Glostrup, Denmark). EBNA2 antibody," kindly obtained from E. Kremmer (Institiit f i r Immunologie, Miinchen, Germany) and F. Crasser (Department of Microbiology, University of Homburg, Saar) was tested using the APAAP method. The tumor was considered positive when more than 10% of tumors cells expressed the differentiation antigens. EBV gene expression was estimated using a semiquantitative grading as previously described." (0, no positive cells; 1, scattered positive cells in a low-power field using 10 X ocular and 10 X objective; 2, few positive cells per medium-power field using 10 X ocular and 25 X objective; 3, positive cells easily seen in each medium-power field; 4, many positive cells in each medium-power field). reaction (PCR) analysis, and Southern blot were used for the detection of EBV. EBV was first detected by PCR and the positive cases were confirmed by either ISH or Southern blot. ISH was performed on paraffin-embedded sections with a fluorescein isothiocyanate (FlTC)-labeled oligonucleotide complementary to small nuclear EBV-encoded RNA1 (EBER-1; Dakopatts). An antifluorescein isothiocyanate antibody APAAP mouse system was used for the detection. EBV-positive control was the Raji cell line and D975 cell line was the negative control. For the PCR analysis, DNA was extracted from frozen tissues using a standard procedure and the EBNAl gene was amplified according to previously published protocols.'* The specificity of the FCR product was assessed after Southern blot using an internal oligonucleotide (5' CCAGTGCCTGGGCCTCT CC 3') labeled with the digoxigenin tailing kit (Boehringer, Meylan, France). The EBV-positive B-cell line Raji was used as a control. Southern blot on genomic material was performed from frozen material using a random primed '*P-labeled probe specific for the BamHl W internal repeats of the virus." Defection of bel-2 rearrangement by PCR analysis. The detection of bcl-2 rearrangements within the major breakpoint region (MBR) and minor cluster region (rncr) was performed according to a previously published protocol?o Specificity of the PCR product was assessed after Southern blot using an internal oligonucleotide: 5' CCCTCCTGCCCTCCTI'CCG 3' for the MBR and 5' GGACCT-TCCTI'GGTGTGTTG 3' for the rncr. These oligonucleotides were labeled with the digoxigenin tailing kit (Boehringer). Positive controls consisted of cases of follicular lymphoma and the negative control was placenta DNA.
Detection of EBV. In situ hybridization (ISH), polymerase chain

Statistical analysis. A x' test modified by the Yates test was
used to assess the association between BCL-2 staining (positive versus negative) and primary localization (brain versus systemic) and LMPl expression (positive versus negative staining).
RESULTS
Histopathology and immunophenotypic study (Table I ) .
Ten of eleven cases (91%) of AR-PBL were classified as immunoblastic (IB) with plasmacytic features, whereas only 1 case was classified as Burkitt's lymphoma (BL). Among the 57 AR-SL, 36 were nodal (63%) and 21 were extranodal (37%). Thirty-nine cases (68%) were large cells (LC) or IB lymphomas (28 LC and 11 IB) and 18 cases (32%) were BL. In all cases, tumor cells were positive for B-cell marker (CD20, L26) and negative for T-cell marker (CD45RO and CD3).
EBV detection. All AR-PBL were associated with EBV, as evidenced by at least two techniques: 9 of 11 cases (82%) were positive by ISH and all cases were positive by PCR technique. In the 8 cases in which Southern blot analysis could be performed, EBV positivity was confirmed. Using immunohistochemistry, 10 of 11 AR-PBL (91%) expressed LMPl (grade 1, 2 cases; grade 2, 1 cases; grade 3, 7 cases; Fig 1B) and 6 of l 1 cases (54%) expressed EBNA2 (grade 1, 1 case; grade 2,2 cases; grade 3 , 2 cases; grade 4, 1 case).
For systemic cases, 11 of 57 AR-SL (19%) were negative using at least two methods previously described for EBV detection. EBV was detected in 46 cases (21 LC, 9 IB, and 16 BL). The frequency of EBV-positive BL cases in this series is higher than in previously published series: but this finding could be explained by the limited number of cases in this category. In EBV-positive cases (46 cases), LMPl was expressed in 21 cases (4 cases of BL [22%] and 17
cases of IBLC [44%]). EBNA2 was expressed in 4 AR-SL
Bcl-2 expression and gene rearrangement (Tables 2 and  3 ). Expression of BCL-2 protein was nearly constant in the cases of AR PBL (10 of 11 [91%]) in more than 50% of cells (Fig 1A) . These 10 cases were IB lymphomas and also expressed LMP1. The BL case did not express either LMPl or BCL-2. By contrast, only 3 of 57 AR-SL cases (5.4%) expressed BCL-2 (Fig IC) . These 3 cases were extranodal lymphomas (gum, lung, and nasopharynx). In all cases, BCL-2-positive reactive lymphocytes could also be observed in nodal lymphomas and were used as internal positive controls (Fig ID) . No rearrangement of the bcl-2 gene within the MBR and the rncr could be shown using PCR.
When BCL-2 expression was assessed in different localizations, the number of cases expressing BCL-2 in primaq brain lymphomas and systemic cases differed significantly (P < .001). BCL-2 expression and LMPl expression were also strongly linked (P < .001).
(7%).
DISCUSSION
AR-PBL are quite different from systemic lymphoma. Nearly all cases are immunoblastic, with plasmacytic features, and their association with EBV is c~nstant.'.'~ Our data confirm the strong association between AR-PBL and EBV because the presence of the virus was demonstrated in all cases using at least two techniques for each case. ISH is a sensitive technique with the major advantage of precise localization of EBV-encoded RNAs on paraffin sections. We could show a good correlation with the results of PCR that was positive in all cases, in contrast to a previous study showing only 50% positive cases." The Southern blot analysis performed in our center confirmed these results in all 8 cases for which enough DNA was available. We also showed that the two latent proteins LMPl and EBNA2 were more frequently expressed in AR-PBL than in systemic lymphomas: all immunoblastic cases expressed LMP1; half of them expressed EBNA2.
BCL-2 is an inner mitochondrial membrane protein that prevents programmed apoptotic cell death.2z.z3 The bcl-2 gene is located on chromosome 18 in the vicinity of the t( 14,18) breakpoint. BCL-2 is overexpressed in follicular lymphomasz4 and in a variety of normal hematopoietic cells during B-or T-cell development and a~tivation.'~ In vitro studies have shown that bcl-2 can be transactivated by LMP1, which results in protection of B cells from programmed apoptotic death.I3*l4 Expression of bcl-2 proto-oncogene enhances cell survival and increases the chances of further DNA alterations. This is a possible mechanism for EBV in the pathogenesis of AR-PBL. However, previous
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The present study shows that nearly all AR-PBL express BCL-2 without DNA rearrangement within the MBR and mcr. This is not found in AR-SL, few of which are positive for BCL-2; these BCL-2-positive cases also express LMPl in numerous cells. All of the AR-PBL cases simultaneously expressing BCL-2 and LMPl were IB in type. In contrast, the only BL case did not express either LMPl or BCL-2. BCL-2 expression seemed to be different in EBV-associated tumors according to their histologic type and primary site. In this study, we have shown a strong association between the primary brain localization and the expression of both BCL-2 and LMP1. BCL-2 is highly expressed in AR-PBL. This finding could be related to LMPl expression. It may also be due to the brain localization of lymphomas. This suggestion makes it difficult to evaluate the influence of each of these factors on BCL-2 expression. A preliminary study of embedded paraffin material in 23 HIV-negative primary brain lymphomas, not associated with EBV, has shown that BCL-2 protein was expressed in only 48% of cases. Similar results have been found in HIV-negative systemic lymphom a~. '~ Therefore, the overexpression of BCL-2 in nearly all AR-PBL may result from the presence of EBV and the expression of the latent protein LMPl. Latent viral proteins LMpl and EBNA2 are overexpressed in AR-PBL, in contrast to AR-SL. These latent viral proteins are known to constitute a target for cytotoxic T-cell-mediated rejection and to initiate a reaction from the host?' Neural tissue is considered to be immunogically privileged, although this is not absolute.3o Conceivably, this peculiar immune response of the brain could allow LMPl and EBNA2 overexpression within infected cells without elic- 
